Literature DB >> 20827447

Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostic markers.

Stefan Tukaj1, Agnieszka Kotlarz, Agnieszka Jóźwik, Zaneta Smoleńska, Ewa Bryl, Jacek M Witkowski, Barbara Lipińska.   

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease which affects approximately 1% of the population worldwide. Recent research on the role of heat shock proteins (Hsps) in RA development indicates that they may have pro- or anti-inflammatory effect, most probably via modulating cytokine secretion. We investigated type Th1 (INFγ, TNFα, IL-2) and type Th2 (IL-10, IL-6, IL-4) cytokine levels in sera of RA patients and healthy controls, using flow cytometric bead array assay, and searched for correlations between the cytokine levels and serum antibodies against bacterial (DnaJ) and human (Hdj1, Hdj2 and Hdj3) Hsp40 proteins, as well as clinical and laboratory parameters. The levels of all cytokines studied were significantly increased in RA patients; the highest increase relative to healthy controls (7-fold) was observed for IL-6 and its levels correlated positively with the antibodies directed to DnaJ and to the C-terminal domain of Hdj2, and with diagnostic parameters (DAS 28, Steinbrocker RTG criteria, ARA/7, ESR, TEN, SW and GH). INFγ levels correlated negatively with DAS 28, ESR, TEN and SW. No correlations were found for TNFα, IL-2 or IL-4. Our results support the hypothesis of Hsp40 involvement in RA as well as indicate that IL-6 serum level is a good marker of the RA activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827447

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  18 in total

1.  Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.

Authors:  Roma Pahwa; Uma Kumar; Nibhriti Das
Journal:  Mol Cell Biochem       Date:  2016-02-23       Impact factor: 3.396

2.  Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis.

Authors:  Jagoda Mantej; Kinga Polasik; Ewa Piotrowska; Stefan Tukaj
Journal:  Cell Stress Chaperones       Date:  2018-11-21       Impact factor: 3.667

3.  Pharmacological studies on the anti-inflammatory and immunomodulatory role of pentoxifylline and its interaction with nitric oxide (NO) in experimental arthritis in rats.

Authors:  Rishi Pal; Manju J Chaudhary; Prafulla Chandra Tiwari; Rajendra Nath; Suresh Babu; Kamlesh Kumar Pant
Journal:  Inflammopharmacology       Date:  2016-09-26       Impact factor: 4.473

4.  Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

Authors:  J Bluett; I Ibrahim; D Plant; K L Hyrich; A W Morgan; A G Wilson; J D Isaacs; A Barton
Journal:  Pharmacogenomics J       Date:  2013-07-16       Impact factor: 3.550

5.  Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis.

Authors:  Voja Pavlovic; Aleksandar Dimic; Sasa Milenkovic; Dane Krtinic
Journal:  J Res Med Sci       Date:  2014-01       Impact factor: 1.852

6.  Interferon-γ and its pathway-associated gene expression in the vaginal tissue of premenopausal females with pelvic organ prolapse.

Authors:  Bing Zhao; Jianguo Yan; Huiyan Wu; Yali Zhou; Dongmei Xu; Mengcai Hu; Shihong Cui
Journal:  Exp Ther Med       Date:  2014-07-29       Impact factor: 2.447

Review 7.  Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment.

Authors:  Camille Jacques; Ilaria Floris; Béatrice Lejeune
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

8.  Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

Authors:  Carl K Edwards; Julie S Green; Hans-Dieter Volk; Michael Schiff; Brian L Kotzin; Hiroaki Mitsuya; Tatsuya Kawaguchi; Ken-Mei Sakata; John Cheronis; David Trollinger; Danute Bankaitis-Davis; Charles A Dinarello; David A Norris; Michael P Bevilacqua; Mayumi Fujita; Gerd-Rudiger Burmester
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

9.  Human Hsp40 proteins, DNAJA1 and DNAJA2, as potential targets of the immune response triggered by bacterial DnaJ in rheumatoid arthritis.

Authors:  Agnieszka Kotlarz; Stefan Tukaj; Konrad Krzewski; Elzbieta Brycka; Barbara Lipinska
Journal:  Cell Stress Chaperones       Date:  2013-02-14       Impact factor: 3.667

10.  Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement.

Authors:  Agata Kosmaczewska; Jerzy Swierkot; Lidia Ciszak; Aleksandra Szteblich; Agnieszka Chrobak; Lidia Karabon; Anna Partyka; Jacek Szechinski; Piotr Wiland; Irena Frydecka
Journal:  Rheumatol Int       Date:  2013-11-13       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.